Product Description
Mechanisms of Action: RTK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, France, Germany, Hungary, Israel, Italy, Korea, Netherlands, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma
Phase 2: Biliary Tract Cancer|Esophageal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Uveal Melanoma
Phase 1: Bone Cancer|Breast Cancer|Head and Neck Cancer|Healthy Volunteers|Melanoma|Other|Prostate Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-001779-15 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-06-26 |
|
| CA248-0003 | P3 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-04-19 |
66% |
| 516-005 | P3 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2024-12-31 |
|
| SITISVEAL-M | P2 |
Active, not recruiting |
Uveal Melanoma |
2024-08-29 |